Outcomes-oriented Evaluation Methodology To strengthen the current evaluation process of the Planning and Evaluation Core (PEC), the Pis have recruited an experienced evaluator from the UPR School of Public Health's Center for Evaluation and Sociomedical Research (CESR), which is a centralized UPR resource, to serve as one ofthe co-leaders. CESR staff members are trained on the latest techniques and approaches to evaluation as well as guidelines to tailor evaluations to fit specific research projects and programs across the cancer continuum (prevention, early detection, diagnosis, treatment and survivorship). CESR is a recognized leader in the science and practice of evaluation of training programs and basic, translational and population-based research, as well as the development of novel innovative approaches to measure success and identify areas that require immediate attention from the Partnership's Pis. CESR currently leads the evaluation processes of the Puerto Rico Clinical and Translational Research Consortium Grant and the CDC's Comprehensive Control Plan. Strategically, this approach leverages the integration of UPR-centralized resources for sustainability and it creates an evaluative culture within the Partnership for effective monitoring, evaluation and analysis of outcomes.

National Institute of Health (NIH)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
United States
Zip Code
Bottsford-Miller, Justin; Choi, Hyun-Jin; Dalton, Heather J et al. (2015) Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clin Cancer Res 21:602-10
Previs, Rebecca A; Coleman, Robert L; Harris, Adrian L et al. (2015) Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res 21:955-61
Cho, Min Soon; Vasquez, Hernan G; Rupaimoole, Rajesha et al. (2014) Autocrine effects of tumor-derived complement. Cell Rep 6:1085-95
Wu, Sherry Y; Lopez-Berestein, Gabriel; Calin, George A et al. (2014) RNAi therapies: drugging the undruggable. Sci Transl Med 6:240ps7
Alvarez-Berríos, Merlis P; Castillo, Amalchi; Rinaldi, Carlos et al. (2014) Magnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell lines. Int J Nanomedicine 9:145-53
Huang, Xuelin; Ning, Jing; Wahed, Abdus S (2014) Optimization of individualized dynamic treatment regimes for recurrent diseases. Stat Med 33:2363-78
Ortiz, Ana Patricia; Pérez-Irizarry, Javier; Soto-Salgado, Marievelisse et al. (2014) Human papillomavirus-related cancers among people living with AIDS in Puerto Rico. Prev Chronic Dis 11:E80
Quintás-Cardama, Alfonso; Choi, Sangbum; Kantarjian, Hagop et al. (2014) Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk 14:327-334.e8
Pradeep, Sunila; Kim, Seung W; Wu, Sherry Y et al. (2014) Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 26:77-91
Tucker, Susan L; Gharpure, Kshipra; Herbrich, Shelley M et al. (2014) Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res 20:3280-8

Showing the most recent 10 out of 41 publications